ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer. (MITO25)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03462212
Recruitment Status : Recruiting
First Posted : March 12, 2018
Last Update Posted : May 10, 2018
Sponsor:
Collaborators:
Istituto Di Ricerche Farmacologiche Mario Negri
Foundation Medicine
Information provided by (Responsible Party):
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Brief Summary:

This trial is a randomized, open-label Phase II multi-center study designed to evaluate the effect of first line therapy of Carboplatin-Paclitaxel-Bevacizumab (in combination and maintenance) vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib (Rucaparib only in maintenance) vs Carboplatin-Paclitaxel-Rucaparib (Rucaparib only in maintenance) on progression-free survival in patients with advanced high grade ovarian cancer.

The randomized phase of the study will be preceded by a single arm Phase I study aiming at evaluating the MTD of the combination Rucaparib-Bevacizumab. Once the MTD has been reached the randomized study will start.


Condition or disease Intervention/treatment Phase
Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer Drug: Carboplatin Drug: Paclitaxel Drug: Bevacizumab Drug: Rucaparib Phase 1 Phase 2

Detailed Description:

Phase I study design:

This is a single-centre, Phase I, open-label, dose-escalation study to evaluate the safety and tolerability of bevacizumab-rucaparib combination and determine the MTD in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

The dose of bevacizumab is fixed in cohort 1, 2 and 3 of the study at 15mg/kg, q 3 weekly.

The dose of rucaparib is evaluated in three cohorts (400 mg BID; 500 mg BID; 600 mg BID).

This trial will enroll at least 3 patients in cohort 1 with dose escalation to rucaparib 500 mg from cohort 1 to 2. Cohort 2 will enroll at least 3 patients with dose escalation to rucaparib 600 mg from cohort 2 to 3.

The standard 3+3 design will be used. Patients will be enrolled in cohort of 3 patients, if no DLT event will be reported among the first 3 patients, a second cohort will be enrolled at the upper dose level. If 1 DLT event is registered in the first cohort, other 3 patients will be enrolled at the same dose.

Phase II study design:

Eligible patients will be randomized 1:1:1 to receive Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel- Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in the following treatment arms:

  • ARM A: Carboplatin AUC 5 + Paclitaxel 175 mg/mq d 1 q 21 for 6 cycles + Bevacizumab 15 mg/kg d 1 q 21 days for 22 cycles (in combination and maintenance);
  • ARM B: Carboplatin AUC 5 + Paclitaxel 175 mg/mq d1 q 21 days for 6 cycles + Bevacizumab 15 mg/kg d1 q 21 for 22 cycles (in combination and maintenance) + Rucaparib at the dose defined by the Phase I study continuously for 2 years (Rucaparib only in maintenance);
  • ARM C: Carboplatin AUC 5 + Paclitaxel 175 mg/mq d1 q 21 days for 6 cycles + Rucaparib 600 mg BID continuously for 2 years (Rucaparib only as maintenance).

Randomization to study treatment will be performed within 28 days following surgery.

Study treatment must be initiated within 4 days of randomization so chemotherapy treatment will be initiated within 32 days from previous surgery.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 234 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase II Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer Preceded by a Phase I Dose Escalation Study on Rucaparib-Bevacizumab Combination.
Actual Study Start Date : February 20, 2018
Estimated Primary Completion Date : November 1, 2018
Estimated Study Completion Date : March 1, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Standard treatment
Carboplatin AUC 5 + Paclitaxel 175 mg/mq d 1 q 21 for 6 cycles + Bevacizumab 15 mg/kg d 1 q 21 days for 22 cycles (in combination and maintenance)
Drug: Carboplatin
chemotherapy medication

Drug: Paclitaxel
chemotherapy medication

Drug: Bevacizumab
Angiogenesis inhibitor

Experimental: Carboplatin + Paclitaxel + Bevacizumab + Rucaparib
Carboplatin AUC 5 + Paclitaxel 175 mg/mq d1 q 21 days for 6 cycles + Bevacizumab 15 mg/kg d1 q 21 for 22 cycles (in combination and maintenance) + Rucaparib at the dose defined by the Phase I study continuously for 2 years (Rucaparib only in maintenance)
Drug: Carboplatin
chemotherapy medication

Drug: Paclitaxel
chemotherapy medication

Drug: Bevacizumab
Angiogenesis inhibitor

Drug: Rucaparib
PARP inhibitor

Experimental: Carboplatin + Paclitaxel + Rucaparib
Carboplatin AUC 5 + Paclitaxel 175 mg/mq d1 q 21 days for 6 cycles + Rucaparib 600 mg BID continuously for 2 years (Rucaparib only as maintenance).
Drug: Carboplatin
chemotherapy medication

Drug: Paclitaxel
chemotherapy medication

Drug: Rucaparib
PARP inhibitor




Primary Outcome Measures :
  1. Phase I Primary Objective: MTD [ Time Frame: 4 months ]
    To identify the Maximum Tolerated Dose (MTD) of the combination Rucaparib-Bevacizumab in stage IIIB-C-IV ovarian cancer patients

  2. Phase II Primary Objective: PFS [ Time Frame: from the date of randomization to the date of documented progression disease, recurrence or death (whichever occurs first), assessed up to 64 months ]
    To compare progression-free survival (PFS) of patients with advanced ovarian, primary peritoneal and Fallopian tube cancer when treated with Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs carboplatin-Paclitaxel-Rucaparib.


Secondary Outcome Measures :
  1. Phase I Secondary Objectives: toxicity of the Rucaparib-Bevacizumab combination in terms of haematologic and non haematologic events [ Time Frame: 4 months ]
    Toxicity will be evaluated according to U.S. NCI Common Toxicity Criteria version 4.03

  2. Phase I Secondary Objectives: maximum plasma concentration (Cmax at Steady State) of Rucaparib [ Time Frame: will be evaluated during cycle 1, on days -7,1,21 ]
    The evaluation of the effect of bevacizumab on rucaparib Cmax at SS will be performed by comparing (in each individual patient) the Cmax during cycle 1, on days 1 and 21, with the Cmax obtained on day -7 in which only Rucaparib will be administered. For these parameters, the following descriptive statistics will be calculated: mean, standard deviation, coefficient of variation, median, and geometric mean.

  3. Phase I Secondary Objectives: minimal plasma concentration (Cmin at Steady State) of Rucaparib [ Time Frame: will be evaluated during cycle 1, on days -7,1,21 ]
    The evaluation of the effect of bevacizumab on rucaparib Cmin at SS will be performed by comparing (in each individual patient) the Cmin during cycle 1, on days 1 and 21, with the Cmax obtained on day -7 in which only Rucaparib will be administered. For these parameters, the following descriptive statistics will be calculated: mean, standard deviation, coefficient of variation, median, and geometric mean.

  4. Phase I Secondary Objectives: Area Under Curve (AUC) [ Time Frame: will be evaluated during cycle 1, on days -7,1,21 ]
    The evaluation of the effect of bevacizumab on rucaparib AUC will be performed by comparing (in each individual patient) during cycle 1, on days 1 and 21, rucaparib AUC with AUC obtained on day -7 in which only Rucaparib will be administered. For this parameters, the following descriptive statistics will be calculated: mean, standard deviation, coefficient of variation, median, and geometric mean.

  5. Phase I Secondary Objectives: Cmax [ Time Frame: will be evaluated during cycle 1, on day1 ]
    The evaluation of the effect of bevacizumab on rucaparib Cmax will be performed by measuring the maximum seric concentration of drug. For this parameter, the following descriptive statistics will be calculated: mean, standard deviation, coefficient of variation, median, and geometric mean.

  6. Phase I Secondary Objectives: Tmax [ Time Frame: will be evaluated during cycle 1, on day1 ]
    The evaluation of the effect of bevacizumab on rucaparib will be performed by measuring the amount of time that the drug is present at the maximum concentration in serum. For this parameter, the following descriptive statistics will be calculated: mean, standard deviation, coefficient of variation, median, and geometric mean.

  7. Phase I Secondary Objectives: AUC (0-24h) [ Time Frame: will be evaluated during cycle 1, on day1 ]
    The evaluation of the effect of bevacizumab on rucaparib will be performed by measuring the AUC during 24 h. For this parameter, the following descriptive statistics will be calculated: mean, standard deviation, coefficient of variation, median, and geometric mean.

  8. Phase II Secondary Objectives: OS [ Time Frame: from the date of randomization to the date of death, assessed up to 64 months ]
    Overall survival

  9. Phase II Secondary Objectives: PFS2 [ Time Frame: from randomisation to second objective disease progression or death, assessed up to 64 months ]
    Progression-free survival 2

  10. Phase II Secondary Objectives: TFST [ Time Frame: from randomisation to the initiation of first subsequent therapy or death of patients, assessed up to 64 months ]
    Time to first subsequent therapy

  11. Phase II Secondary Objectives: TSST [ Time Frame: from randomisation to the initiation of second subsequent therapy or death, assessed up to 64 months ]
    Time to second subsequent therapy

  12. Phase II Secondary Objectives: ORR [ Time Frame: 64 months ]
    Overall response rate

  13. Phase II Secondary Objectives: Safety and tolerability [ Time Frame: 64 months ]
    Safety and tolerability will be evaluated by U.S. National Cancer Institute Common Toxicity Criteria Adverse Event (NCI CTCAE) version 4.03 and the number of dose reductions

  14. Phase II Secondary Objectives: PRO for PHYSICAL WELL-BEING [ Time Frame: 64 months ]
    Patient-reported outcome (PRO) of disease-related symptoms will be recorded utilizing the disease-related symptoms - physical (DRS-P) subscale of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) FACT-Ovarian Symptom Index 18 (FOSI-18) changes and using Euro-Quality of Life 5D (EQ-5D) tool (Appendix A).

  15. Phase II Secondary Objectives: PRO for SOCIAL/FAMILY WELL-BEING [ Time Frame: 64 months ]
    Patient-reported outcome (PRO) of disease-related symptoms will be recorded utilizing the disease-related symptoms - physical (DRS-P) subscale of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) FACT-Ovarian Symptom Index 18 (FOSI-18) changes and using Euro-Quality of Life 5D (EQ-5D) tool (Appendix A).

  16. Phase II Secondary Objectives: PRO for EMOTIONAL WELL-BEING [ Time Frame: 64 months ]
    Patient-reported outcome (PRO) of disease-related symptoms will be recorded utilizing the disease-related symptoms - physical (DRS-P) subscale of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) FACT-Ovarian Symptom Index 18 (FOSI-18) changes and using Euro-Quality of Life 5D (EQ-5D) tool (Appendix A).

  17. Phase II Secondary Objectives: PRO for FUNCTIONAL WELL-BEING [ Time Frame: 64 months ]
    Patient-reported outcome (PRO) of disease-related symptoms will be recorded utilizing the disease-related symptoms - physical (DRS-P) subscale of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) FACT-Ovarian Symptom Index 18 (FOSI-18) changes and using Euro-Quality of Life 5D (EQ-5D) tool (Appendix A).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Women aged >=18 years at the time of study inclusion;
  2. Patients with newly diagnosed, histologically confirmed, high grade serous, high grade endometrioid, clear cell FIGO stage IIIB-C-IV epithelial ovarian cancer, primary peritoneal cancer and / or Fallopian-tube cancer. Patients with mixed histology (carcinosarcoma) are eligible providing that high grade tumor represent more than 50% of the total histology; other histotypes may be enrolled providing BRCA mutation is present.

    Stage III patients should have had one attempt at optimal debulking surgery (upfront or interval debulking). Stage IV patients must have had either a biopsy and/or upfront or interval debulking surgery;

  3. Archival tumor tissue available. At progression fresh biopsy is optional for patients willing to submit ;
  4. ECOG Performance Status of 0-1;
  5. Measurable and not measurable disease;
  6. Adequate renal and hepatic function, defined as:

    • Total serum bilirubin ≤ 1.5 institutional ULN unless patient has Gilbert's syndrome in which case total serum bilirubin must be <2 ULN for the institution AST and/or ALT ≤ 2.5 x ULN for the institution. (or ≤ 5 x ULN if liver metastases are present);
    • Alkaline phosphatase < 1.5 x ULN for the institution (if > 1.5 x ULN, then alkaline phosphatase liver fraction must be < 1.5 ULN)
    • Serum creatinine ≤ 1.5 x ULN for the institution (or calculated creatinine clearance ≥ 45 mL/min/1.73 m2);
  7. Adequate bone marrow function, defined as:

    • Total leukocytes 2.5 x 109/L;
    • ANC 1.5 x 109/L;
    • Platelet count 100 x 109/L;
  8. Able to understand and give written informed consent;
  9. Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to study enrollment.

Exclusion Criteria:

  1. Women who are pregnant or lactating;
  2. Presence of brain or other central nervous system metastases, not adequately controlled by treatment;
  3. Prior Anticancer treatment;
  4. Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 3 weeks prior to randomization;
  5. Another primary malignancy except for:

    1. Curatively treated non-melanoma skin cancer;
    2. Breast cancer treated curatively ≥5 years ago, or other solid tumor treated curatively ≥5 years ago, without evidence of recurrence;
    3. Synchronous endometrioid endometrial cancer (except for Stage 1A G1/G2);
  6. Known active HIV, hepatitis B or C infection;
  7. Concurrent treatment with immunosuppressive or investigational agents;
  8. History or evidence of thrombotic or hemorrhagic disorders; including cerebrovascular accident (CVA) / stroke or transient ischemic attack (TIA) or subarachnoid haemorrhage within _6 months prior to the first study treatment);
  9. Clinically significant (i.e. active) cardiovascular disease, including:

    • Myocardial infarction or unstable angina within _6 months prior to the first study treatment;
    • New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF);
    • Serious cardiac arrhythmia requiring medication (with the exception of atrial fibrillation or paroxysmal supraventricular tachycardia);
    • Peripheral vascular disease > grade 3 (i.e.symptomatic and interfering with activities of daily living requiring repair or revision);
  10. Serious active infection requiring i.v. antibiotics at enrolment;
  11. Known hypersensitivity to any of the study drugs or excipients (including cremophor and hamster Ovary cell products);
  12. Evidence of any other medical conditions (such as psychiatric illness, peptic ulcer, etc.), physical examination or laboratory findings that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment related complications;
  13. Prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with absorption of study drug;
  14. Received administration of strong CYP1A2 or CYP3A4 inhibitors ≤7 days prior to first dose of Rucaparib or have on-going requirements for these medications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03462212


Contacts
Contact: Domenica Lorusso, MD 0223903697 domenica.lorusso@istitutotumori.mi.it
Contact: Serena Giolitto, MSc 0223903882 serena.giolitto@istitutotumori.mi.it

Locations
Italy
National Cancer Institute Recruiting
Milan, Italy, 20133
Sponsors and Collaborators
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Istituto Di Ricerche Farmacologiche Mario Negri
Foundation Medicine
Investigators
Principal Investigator: Domenica Lorusso, MD National Cancer Institute (NCI)

Additional Information:
Publications of Results:
du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U; Gynecologic Cancer Intergroup; AGO-OVAR; ANZGOG; EORTC; GEICO; GINECO; GOG; JGOG; MRC/NCRI; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG; IGCS; Organizational team of the two prior International OCCC. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16 Suppl 8:viii7-viii12.

Other Publications:
De Bono JS, Mina LA, Gonzalez M, Curtin NJ, Wang E, Henshaw JW, et al. First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. J Clin Oncol. 2013;31(suppl):2580.
Iain A. McNeish, Amit M. Oza, Robert L. Coleman, et al. Results of ARIEL2: A Phase II trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. J Clin Oncol 33, 2015 (suppl; abstr 5508)
Gourley, C. McCavigan, A Perren, T et al Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. Abstract 5502 ASC0 2014

Responsible Party: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
ClinicalTrials.gov Identifier: NCT03462212     History of Changes
Other Study ID Numbers: INT 148-17
First Posted: March 12, 2018    Key Record Dates
Last Update Posted: May 10, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Fallopian Tube Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Fallopian Tube Diseases
Adnexal Diseases
Genital Diseases, Female
Paclitaxel
Rucaparib
Albumin-Bound Paclitaxel
Bevacizumab
Carboplatin
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors